Standard
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. / Heitz, F.; Harter, P.; Åvall-lundqvist, E.; Reuss, A.; Pautier, P.; Cormio, G.; Colombo, N.; Reinthaller, A.; Vergote, I.; Poveda, A.; Ottevanger, P.b.; Hanker, L.c.; Leminen, A.; Alexandre, J.; Canzler, U.; Sehouli, J.; Herrstedt, J.; Fiane, B.; Merger, M.; Du Bois, A.
I:
Gynecologic Oncology, Bind 152, Nr. 2, 2019, s. 235-242.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Heitz, F, Harter, P, Åvall-lundqvist, E, Reuss, A, Pautier, P, Cormio, G, Colombo, N, Reinthaller, A, Vergote, I, Poveda, A, Ottevanger, PB, Hanker, LC, Leminen, A, Alexandre, J, Canzler, U, Sehouli, J
, Herrstedt, J, Fiane, B, Merger, M & Du Bois, A 2019, '
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12',
Gynecologic Oncology, bind 152, nr. 2, s. 235-242.
https://doi.org/10.1016/j.ygyno.2018.11.008APA
Heitz, F., Harter, P., Åvall-lundqvist, E., Reuss, A., Pautier, P., Cormio, G., Colombo, N., Reinthaller, A., Vergote, I., Poveda, A., Ottevanger, P. B., Hanker, L. C., Leminen, A., Alexandre, J., Canzler, U., Sehouli, J.
, Herrstedt, J., Fiane, B., Merger, M., & Du Bois, A. (2019).
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Gynecologic Oncology,
152(2), 235-242.
https://doi.org/10.1016/j.ygyno.2018.11.008Vancouver
Heitz F, Harter P, Åvall-lundqvist E, Reuss A, Pautier P, Cormio G o.a.
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Gynecologic Oncology. 2019;152(2):235-242.
https://doi.org/10.1016/j.ygyno.2018.11.008Author
Heitz, F. ; Harter, P. ; Åvall-lundqvist, E. ; Reuss, A. ; Pautier, P. ; Cormio, G. ; Colombo, N. ; Reinthaller, A. ; Vergote, I. ; Poveda, A. ; Ottevanger, P.b. ; Hanker, L.c. ; Leminen, A. ; Alexandre, J. ; Canzler, U. ; Sehouli, J. ; Herrstedt, J. ; Fiane, B. ; Merger, M. ; Du Bois, A. / Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. I: Gynecologic Oncology. 2019 ; Bind 152, Nr. 2. s. 235-242.
Bibtex
@article{f843269383134b3f82df1ad424aa0b19,
title = "Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12",
author = "F. Heitz and P. Harter and E. {\AA}vall-lundqvist and A. Reuss and P. Pautier and G. Cormio and N. Colombo and A. Reinthaller and I. Vergote and A. Poveda and P.b. Ottevanger and L.c. Hanker and A. Leminen and J. Alexandre and U. Canzler and J. Sehouli and J. Herrstedt and B. Fiane and M. Merger and {Du Bois}, A.",
year = "2019",
doi = "10.1016/j.ygyno.2018.11.008",
language = "English",
volume = "152",
pages = "235--242",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "2",
}
RIS
TY - JOUR
T1 - Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12
AU - Heitz, F.
AU - Harter, P.
AU - Åvall-lundqvist, E.
AU - Reuss, A.
AU - Pautier, P.
AU - Cormio, G.
AU - Colombo, N.
AU - Reinthaller, A.
AU - Vergote, I.
AU - Poveda, A.
AU - Ottevanger, P.b.
AU - Hanker, L.c.
AU - Leminen, A.
AU - Alexandre, J.
AU - Canzler, U.
AU - Sehouli, J.
AU - Herrstedt, J.
AU - Fiane, B.
AU - Merger, M.
AU - Du Bois, A.
PY - 2019
Y1 - 2019
U2 - 10.1016/j.ygyno.2018.11.008
DO - 10.1016/j.ygyno.2018.11.008
M3 - Journal article
C2 - 30466805
VL - 152
SP - 235
EP - 242
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 2
ER -
